Geoff Mcdonough - Jan 2, 2024 Form 4 Insider Report for Generation Bio Co. (GBIO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Benjamin Waters, Attorney-in-Fact
Stock symbol
GBIO
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2024, 04:35 PM
Previous filing
Dec 5, 2023
Next filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GBIO Common Stock 1.29M Jan 2, 2024 Direct F1
holding GBIO Common Stock 226K Jan 2, 2024 By 2018 Trust F2
holding GBIO Common Stock 275K Jan 2, 2024 By 2020 Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBIO Stock Option (right to buy) Award $0 +506K $0.00 506K Jan 2, 2024 Common Stock 506K $1.86 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,445 shares acquired under the company's employee stock purchase plan since December 5, 2023.
F2 The securities are directly held by the McDonough Family 2018 Irrevocable Trust, or the 2018 Trust. The reporting person is the settlor of the 2018 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2018 Trust, and the 2018 Trust is for the benefit of Graeme and Owen McDonough. The reporting person may be deemed to beneficially own the shares of common stock owned by the 2018 Trust.
F3 The securities are directly held by the McDonough Family 2020 Irrevocable Trust, or the 2020 Trust. The reporting person is the settlor of the 2020 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2020 Trust, and the 2020 Trust is for the benefit of Allison, Graeme and Owen McDonough. The reporting person may be deemed to beneficially own the shares of common stock owned by the 2020 Trust.
F4 The option to purchase 506,250 shares of common stock was granted on January 2, 2024. The shares underlying the option vest over four years, with 25% of the shares vesting on January 2, 2025 and the remaining shares vesting in equal quarterly installments thereafter.